OncoMed Pharmaceuticals and Fluidigm annouce strategic collaboration
OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation announced a new initiative to apply Fluidigm’s microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells. The collaboration will combine Fluidigm’s microfluidic platforms with OncoMed’s proprietary cancer stem cell sorting technology to generate unique tools for analyzing, quantifying and developing treatments directed at a highly tumorigenic cell population.
In the initial application, OncoMed will apply Fluidigm’s BioMark™ System along with Fluidigm’s Dynamic Array™ integrated fluidic circuits (IFCs) to perform detailed gene expression analysis of solid tumors at the whole tumor and single-cell level. This phase will track changes in cancer stem cells found in human tumors following treatment with OncoMed’s pipeline of therapeutic monoclonal antibodies. The companies will apply this same technology to analyze tumor heterogeneity and cancer stem cell frequency across OncoMed’s human tumor bank which includes approximately one hundred human tumor biopsies that have been engrafted and minimally passaged in immunocompromised mice. The OncoMed/Fluidigm collaboration also has the potential to include novel and next-generation microfluidic and tissue sample-preparation technologies that Fluidigm is currently developing.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Resilience towards food addiction
Synthon Announces Successful Outcomes from Phase III Study of Synthon’s Glatiramer Acetate
Shut-off switch for lymphoma - Important tumor suppressor discovered in immune cells
List_of_mustard_diseases
List_of_coffee_diseases

ACHEMA 2024 sets the tone for a more sustainable and competitive process industry
Iowa State researcher produces, ships only H1N1 vaccine available for swine
Ibidi establishes partnership with Seahorse Bioscience
European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy - No new concerns for Pandemrix or other vaccines on the basis of available evidence

Endogenous molecule protects from life-threatening complications after stem-cell transplantation - Researchers find that an antimicrobial molecule modifies T-cell-signalling and thus attenuates overshooting immune reactions
